Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...
PA­LO AL­TO, CA — Af­ter giv­ing ar­ti­fi­cial in­tel­li­gence tools to thou­sands of em­ploy­ees, Bris­tol My­ers Squibb is now work­ing to get a han­dle on the costs of the tech­nol­o­gy and where ...
Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act.
Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...
An extended-release version of deucrictibant reduced patients’ mean monthly attack rate by 83% compared to placebo, meeting ...
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
CART01; Ori bags $120M deal; Reckitt invests $600M in US; Astellas expands Ireland; Hovione opens NJ facility.
FDA grants accelerated approval to Ultragenyx's Sanfilippo gene therapy UX111, weeks after the biotech's Angelman Phase 3 ...
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
The FDA ap­proved a new com­bi­na­tion reg­i­men from Eli Lil­ly for cer­tain breast can­cer pa­tients, a reg­i­men that in­cludes Lil­ly’s oral se­lec­tive es­tro­gen re­cep­tor de­grad­er (SERD) ...
Anthropic posts a corporate development role for life sciences dealmaking, paying up to $600,000, as its biotech push and IPO ...
China's new five-year plan targets 20% annual pharma revenue growth and a quarter of the world's first-in-class drugs by 2030 ...